RE: This was expected!27 Apr 2023 15:46
Hi PharmaGiles,
You can see the effect of the month-on-month total prescription volume in the table in the update. January was only 3% higher than December with Feb only 1% higher than that. Clearly driven by the fact that Shield had to hire 16 "direct sales representatives" who were previously part of a "contract sales team" (A big difference moving forward given they will also only concentrate on Accrufer moving forwards) and bed in the 14 new people that joined them.
Because Jan and Feb were fairly flat (1% difference) it is easy to work out the monthly sales. March was a minimum of 3,990 of the "over" 10,500 sales that were booked so we are talking c. 6,510 between Jan and Feb. At 1% difference that is near as damn it 3,240 in Jan and 3,270 in Feb. Thus whilst the 38% doesn't immediately feel like a big uplift it was c. 21% (again see the table) which is a marked improvement.
A 22-person contracted sales team(which I take to mean outsourced) achieved 9.324 sales. A combined new dedicated team of the first 30 sales persons is showing through the March figure that it can achieve c. 12,000 sales and half of it (14 people) barely got going in March and so can likely deliver much more given more time.
Unfortunately, the market is seeing a rather flat Q1 figure and saying not good enough show me more but in my opinion, it is being lazy and reverting to type (current market conditions and so attitude). There is clearly a lag effect on commencing work and actually contributing meaningful sales which should clear itself much more in Q2 for those that were added in February and to some extent the 36 people that came on board on 1st April.
The marked increase in first-time prescribers looks to have been completely bypassed by the market and it is important because it widens the reach and enables more self-driven repeat business to be realised.
I am trusting that management will better explain things in the investor call and show commitment to quarterly updates which I have asked about. It is clear to me that STX is now on a steep sales curve which will show itself in the next couple of updates/interim reports. Then let's see where the valuation sits.